Eli Lilly’s retatrutide is under investigation in another six Phase III trials.

The FDA has approved Orforglipron as the second oral GLP-1 receptor agonist for weight management in adults with obesity or overweight with comorbidities. This once-daily tablet is to be ...

(HealthDay News) — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...

As patents on semaglutide expire, manufacturers are poised to introduce cheaper generic versions of blockbuster drugs, with far-reaching effects on the obesity crisis. Megan Tatum reports.

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon) receptor agonist.

GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a phase 2 trial in Chinese ...

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study  IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Eli Lilly and Company report top-line phase 3 clinical trial results for its investigational GLP-1, GIP, and glucagon agonist ...

Kailera Therapeutics—one of the biggest money-raisers of 2025—is now planning to go public as it seeks further funding to push its obesity portfolio through the clinic. | Kailera Therapeutics—one of ...